Wynnefield continues to invest in Unigene Laboratories

By Lisa Kerner

Charlotte, N.C., Jan. 25 - Unigene Laboratories, Inc. investors led by Wynnefield Partners Small Cap Value, LP bought 376,500 shares of the company's stock between Dec. 19 and Jan. 22.

The shares were priced from $1.53 to $2.17, according to a schedule 13D filing with the Securities and Exchange Commission.

The investors beneficially own 4,456,251 shares, or 5.1%, of the Fairfield, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.